Navigation Links
Genomic signature in post-menopausal women may explain why pregnancy reduces breast cancer risk
Date:4/5/2011

ORLANDO, FL (April 5, 2011) Women who have children, particularly early in life, have a lower lifetime risk of breast cancer compared with women who do not. Now, Fox Chase Cancer Center researchers have identified a gene expression pattern in breast tissue that differs between post-menopausal women who had children and post-menopausal women who did not. The results will help scientists understand why pregnancy reduces breast cancer risk and may help them develop chemopreventive strategies that can provide similar protection for women who did not have children.

Pregnancy triggers differentiation and growth of breast tissue; however breast tissue in post-menopausal women looks similar regardless of childbearing history. That similarity has left researchers wondering why pregnancy is protective throughout a woman's life. This study starts to explain that effect, says Ricardo Lpez de Cicco, PhD, a senior research associate at Fox Chase, who will present the work at the AACR 102nd Annual Meeting 2011 on Tuesday, April 5.

"When a woman has multiple pregnancies beginning at a relatively young age, we see a protective effect against breast cancer," Lopez says. "In this study, we identified a post-pregnancy genomic signature that can still be seen even after menopause. That is very important because it could begin to help us understand why women who have children early benefit from a reduced risk of breast cancer throughout their lives."

By comparing gene expression in breast tissue from 44 post-menopausal women who had children and 21 post-menopausal women who did not, the team identified 208 genes that are differentially expressed. The signature was subsequently validated in an independent cohort of 61 post-menopausal women, 38 who had children and 23 who did not.

"We are now quite sure that these 208 genes 305 transcripts represent the genomic signature of the effects of pregnancy," says Jose Russo, MD, director of the Breast Cancer Research Laboratory at Fox Chase, who led the new study.

"Finding that signature was our end goal," Russo emphasizes. "If we want to develop chemopreventive strategies, then we need a standard or test to see if they are working. This genomic signature may be that standard."

Among the differentially expressed genes, the team detected several that are involved in processing RNA transcripts. Russo hypothesizes that the increased RNA processing proteins help ensure that no abnormal proteins are made, thereby reducing the likelihood of abnormal growth and cancer.

The team also saw reduced expression of cancer-associated genes in breast tissue from women who had children. For example, the insulin-like growth factor receptor, which is associated with increased cell proliferation, was expressed at a lower level in the samples from women who had children (parous) compared to samples from women who did not (nulliparous). Similarly, genes involved in stem cell maintenance were down-regulated, which may be because the mammary stem cells have already undergone proliferation and differentiation in the women who had children. By contrast, the stem cells are still poised to grow and produce new mammary tissue in the women who did not have children. Some theories of oncogenesis suggest that cancers arise from stem cells that go awry.


'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. New genomics research investigates metastatic childhood cancers
2. Promise of genomics research needs a realistic view
3. NHGRI charts course for the next phase of genomics research
4. Tufts University calls for moderate approach to teaching personalized genomic testing
5. Genomic markers may head off thousands of thyroid surgeries
6. Forces for cancer spread: Genomic instability and evolutionary selection
7. Genomic Systems announces moratorium on studying and treating terminal cancer has ended
8. La Jolla Institute to develop San Diegos first center for RNAi genomics research
9. Radiation pharmacogenomics identifies biomarkers that could personalize cancer treatment
10. St. Jude researcher receives grant to focus on cancer pharmacogenomics in children
11. New genomic marker for tuberculosis may help identify patients who will develop the disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... ... financial consultation services to residents in the Sacramento/Folsom region, is initiating a charity ... facility. , The Another Choice Another Chance treatment center in Sacramento works to ...
(Date:12/7/2016)... ... December 07, 2016 , ... A. Kevin Spann Insurance, ... families throughout the Five Boroughs, is launching a charity drive to raise funds that ... the traditions and spirit of marines and Navy FMF Corpsmen. Working closely with the ...
(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. John D. Rachel ... a portion of proceeds to two local organizations: North Chicago Animal Control and Friends ... is a team of authorized and trained volunteers who support rescued animals held ...
(Date:12/7/2016)... ... December 07, 2016 , ... The medical profession is well aware that heart ... major study analyzing heart attacks among 138,602 people recorded a 35% higher number of ... would all agree of course–no time of year is a good time for a ...
(Date:12/7/2016)... Norwalk, CT (PRWEB) , ... December 07, 2016 ... ... the Integrated Infertility and Wellness (IFW) Program at Reproductive Medicine Associates of Connecticut ... which now has a team of three acupuncturists to help patients realize their ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , Dec. 7, 2016 According to responses from ... than one-third (38%) of patients with non-small cell lung cancer ... factor receptor (EGFR) genetic mutation status. The findings of the ... LBA ID #6067 #P3.02b ) at the 2016 World ... . The survey results revealed an overall ...
(Date:12/7/2016)... Conn. , Dec. 7, 2016 ... II trial in patients with unresectable malignant pleural ... survival (PFS). The data, presented at the 17 ... in Vienna , showed nintedanib ... to placebo plus pemetrexed/cisplatin, with a significantly improved ...
(Date:12/7/2016)... Today, Stock-Callers.com presents four Biotech equities ... ), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH ), ProNAi ... (NASDAQ: AVXS ). From its peak in July ... reach a level equal to what it saw at the ... for the year, it has still out-performed other market sectors, ...
Breaking Medicine Technology: